Ivana Sestak1, Francisco Sapunar, Jack Cuzick. 1. Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, UK. ivana.sestak@cancer.org.uk
Abstract
PURPOSE:Carpal tunnel syndrome (CTS) is a condition in which the median nerve is compressed, leading to pain and muscle weakness in the fingers and hand. Aromatase inhibitors lead to profound estrogen suppression and may be expected to increase the risk of CTS in postmenopausal women receiving adjuvant therapy for early breast cancer. PATIENTS AND METHODS: The current analyses were based on the 100-month median follow-up data in postmenopausal women in the two monotherapy arms (anastrozole, n = 3,092; tamoxifen, n = 3,094). Here, we investigate the natural history of patients who presented with CTS during adjuvant treatment for breast cancer and the relative importance of a range of known risk factors for CTS. RESULTS: After 100 months of follow-up, 80 cases (2.6%) of CTS were reported in the anastrozole arm, compared with 23 cases (0.7%) in the tamoxifen arm (P < .0001). The majority of CTS cases were reported as mild to moderate intensity and occurred early. None of the women stopped treatment medication as a result of CTS. CTS was significantly increased for women who used prior hormone replacement therapy (P = .007) or received prior chemotherapy (P = .01). Those who were 60 years of age or older at entry were at lower risk of CTS compared with their counterparts (P = .002). CONCLUSION: Although the use of anastrozole is associated with a greater incidence of CTS, it is rare, and most cases were of mild to moderate intensity and short duration. CTS has little impact on the overall risk-to-benefit ratio for the use of anastrozole in postmenopausal women with early breast cancer.
RCT Entities:
PURPOSE:Carpal tunnel syndrome (CTS) is a condition in which the median nerve is compressed, leading to pain and muscle weakness in the fingers and hand. Aromatase inhibitors lead to profound estrogen suppression and may be expected to increase the risk of CTS in postmenopausal women receiving adjuvant therapy for early breast cancer. PATIENTS AND METHODS: The current analyses were based on the 100-month median follow-up data in postmenopausal women in the two monotherapy arms (anastrozole, n = 3,092; tamoxifen, n = 3,094). Here, we investigate the natural history of patients who presented with CTS during adjuvant treatment for breast cancer and the relative importance of a range of known risk factors for CTS. RESULTS: After 100 months of follow-up, 80 cases (2.6%) of CTS were reported in the anastrozole arm, compared with 23 cases (0.7%) in the tamoxifen arm (P < .0001). The majority of CTS cases were reported as mild to moderate intensity and occurred early. None of the women stopped treatment medication as a result of CTS. CTS was significantly increased for women who used prior hormone replacement therapy (P = .007) or received prior chemotherapy (P = .01). Those who were 60 years of age or older at entry were at lower risk of CTS compared with their counterparts (P = .002). CONCLUSION: Although the use of anastrozole is associated with a greater incidence of CTS, it is rare, and most cases were of mild to moderate intensity and short duration. CTS has little impact on the overall risk-to-benefit ratio for the use of anastrozole in postmenopausal women with early breast cancer.
Authors: Ora Singer; Tessa Cigler; Anne B Moore; Alana B Levine; Keith Hentel; Lily Belfi; Huong T Do; Lisa A Mandl Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: A Robidoux; E Rich; N J Bureau; S Mader; D Laperrière; M Bail; N Tremblay; M Patenaude; J Turgeon Journal: Curr Oncol Date: 2011-12 Impact factor: 3.677
Authors: Dawn L Hershman; Joseph M Unger; Katherine D Crew; Danielle Awad; Shaker R Dakhil; Julie Gralow; Heather Greenlee; Danika L Lew; Lori M Minasian; Cathee Till; James L Wade; Frank L Meyskens; Carol M Moinpour Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Jennifer Y Sheng; Amanda L Blackford; Aditya Bardia; Raghunandan Venkat; Gedge Rosson; Jon Giles; Daniel F Hayes; Stacie C Jeter; Zhe Zhang; Jill Hayden; Anne Nguyen; Anna Maria Storniolo; Karineh Tarpinian; Norah Lynn Henry; Vered Stearns Journal: Breast Cancer Res Treat Date: 2019-05-11 Impact factor: 4.872